Readers Who Disagree ... Commentary Roundup

The Merck-Gardasil business has sparked some debate. You can read it here.  A sampling:

• "The specter of being tagged as a 'powerful, behind-the-scenes lobbyist' ... weighed more heavily in Merck's decision to drop this lobbying effort than any fear of the religious right or the anti-vaccine crowd," says Bruce Grant.

• "How can you label those who prefer to take a cautious approach to this as 'pro-cancer' and 'anti-science'?" says Steve Woodruff.

• "I disagree with Edwards," says Fard Johnmar.